Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
First Wave BioPharma, Inc. (AZRX)
|
Add to portfolio |
|
|
|
| Price: |
$1.58
| | Metrics |
| OS: |
7.15
|
M
| |
-929
|
% ROE
|
| Market cap: |
$11.3
|
M
| |
|
|
|
Net cash:
|
$1.08
|
M
| |
$0.15
|
per share
|
|
EV:
|
$10.2
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($6.1)
|
M
| |
|
|
|
EBIT
|
($6.1)
|
M
| |
|
|
| EPS |
($6.65)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 20.8 | 0.0 | 0.0 | 0.0 | 0.0 | -1.0 | -8.0 | -1.2 |
| Revenue growth | | | | | -100.0% | -87.3% | 563.1% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 20.8 | 0.0 | 0.0 | 0.0 | 0.0 | -1.0 | -8.0 | -1.2 |
| Gross margin | 100.0% | | | | | 100.0% | 100.0% | 100.0% |
| Research and development | 8.8 | 17.0 | 5.9 | 8.7 | 5.8 | 2.4 | 2.5 | 1.4 |
| General and administrative | 12.0 | 18.4 | 7.3 | 6.1 | 7.5 | 7.7 | 4.1 | 3.3 |
| EBITA | -12.7 | -56.2 | -25.9 | -14.0 | -12.7 | -9.5 | -5.6 | -4.0 |
| EBITA margin | -61.1% | | | | | 937.4% | 70.7% | 336.0% |
| Amortization of intangibles | | 0.5 | 0.5 | 0.8 | 0.7 | 0.7 | 0.7 | 0.7 |
| EBIT | -12.7 | -56.7 | -26.4 | -14.7 | -13.4 | -10.2 | -6.3 | -4.7 |
| EBIT margin | -61.1% | | | | | 1006.8% | 79.4% | 393.6% |
| Pre-tax income | -14.6 | -58.5 | -32.7 | -15.2 | -13.5 | -11.1 | -14.6 | -5.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -15.0 | -84.5 | -41.7 | -15.2 | -13.5 | -11.1 | -14.6 | -5.9 |
| Net margin | -72.1% | | | | | 1093.0% | 183.2% | 493.6% |
| |
| Diluted EPS | ($20.85) | ($1,988.53) | ($36,288,989.57) | ($22,320,126.47) | $15,379,110.23 | ($1.04) | ($2.24) | ($1.63) |
| Shares outstanding (diluted) | 0.7 | 0.0 | 0.0 | 0.0 | 0.0 | 10.6 | 6.5 | 3.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|